Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

David A. D'Alessio

University of Cincinnati

2180 East Galbraith Road

Building E

Room 315

[email]@ucmail.uc.edu

Name/email consistency: high

[Claim this account]

Affiliations

University of Cincinnati, 2180 East Galbraith Road, Building E, Room 315. 2012
Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism. 2009 - 2011
Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati, Cincinnati VA Medical Center, USA. 2010
Department of Medicine, University of Cincinnati, Cincinnati, Ohio 45267, USA. 2004 - 2007
University of Cincinnati, Division of Endocrinology, ML 0547, Cincinnati, USA. 2004 - 2005

References

Suppression of food intake by glucagon-like Peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4. Jessen, L., Aulinger, B.A., Hassel, J.L., Roy, K.J., Smith, E.P., Greer, T.M., Woods, S.C., Seeley, R.J., D'Alessio, D.A. Endocrinology (2012) [Pubmed]
What if Gut Hormones Aren't Really Hormones: DPP-4 Inhibition and Local Action of GLP-1 in the Gastrointestinal Tract. D'Alessio, D.A. Endocrinology (2011) [Pubmed]
Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target? D'Alessio, D.A. Diabetes (2010) [Pubmed]
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. D'Alessio, D.A., Denney, A.M., Hermiller, L.M., Prigeon, R.L., Martin, J.M., Tharp, W.G., Saylan, M.L., He, Y., Dunning, B.E., Foley, J.E., Pratley, R.E. J. Clin. Endocrinol. Metab. (2009) [Pubmed]
Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. D'Alessio, D., Lu, W., Sun, W., Zheng, S., Yang, Q., Seeley, R., Woods, S.C., Tso, P. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2007) [Pubmed]
Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. D'Alessio, D.A., Vahl, T.P. Curr. Diab. Rep. (2005) [Pubmed]
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. D'Alessio, D.A., Vahl, T.P. Am. J. Physiol. Endocrinol. Metab. (2004) [Pubmed]
Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. D'Alessio, D., Vahl, T., Prigeon, R. Horm. Metab. Res. (2004) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.